Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
BMO Capital Reiterates Outperform Rating on Merck (MRK)
November 25, 2024 8:01 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $136.00 price target on Merck (NYSE: MRK).
The analyst comments "ZENITH trial has been stopped early due to overwhelming efficacy of sotatercept in functional class III/IV PAH patients. Following the compelling... More
